Recent clinical findings in Rheumatoid Arthritis captured in Pharmerit's health economic model
Recent clinical findings, reported in the Guardian, indicated that early treatment of aggressive rheumatoid arthritis (RA) with an anti-TNF agent caused on-going underlying joint damage to be almost completely halted.
This element of underlying latent disease progression has been incorporated in Pharmerit's RA health economic model recently developed by Professor Ben van Hout, PhD, Scientific Director of Pharmerit. This RA model incorporates several other additional disease characteristics, providing a template to assess the value of treatments which target more than one aspect of RA disease activity. A cost-effectiveness analysis using the RA model was presented at the 2009 EULAR conference in Copenhagen, Denmark.
|